Article Text

Download PDFPDF

TARA study: a new perspective on tapering drugs in RA
  1. Debashish Mishra,
  2. Arghya Chattopadhyay,
  3. Sanjay Jain,
  4. Varun Dhir
  1. Clinical Immunology and Rheumatology services, Department of Internal Medicine, PGIMER, Chandigarh, India
  1. Correspondence to Dr Varun Dhir, Internal Medicine (Rheumatology Unit), Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India; varundhir{at}

Statistics from

We read with great interest the article on ‘Gradual tapering TNF inhibitors vs conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: first-year results of the randomised controlled TARA study’1by van Mulligen et al. This was the first head-to-head comparison between two tapering strategies—biological versus conventional in rheumatoid arthritis. The final results favour tapering tumour necrosis factor inhibitors (TNFis) before conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). However, certain points need clarifications.

First, many patients in the …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles